Clinical Trials Logo

Clinical Trial Summary

Prospective, multicenter, randomized, double-blind, parallel group, placebo- controlled, efficacy and safety phase 3 study of an intravenous human plasma- derived C1 esterase inhibitor (C1-INH) concentrate in participants with congenital C1-INH deficiency for the treatment and pre-procedure prevention of acute hereditary angioedema attacks


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06361537
Study type Interventional
Source Octapharma
Contact Patrick M Murphy
Phone 8663371868
Email ctgov@clinicalresearchmgt.com
Status Recruiting
Phase Phase 3
Start date April 30, 2024
Completion date December 2025